Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Liabilities: 2013-2024

Historic Total Liabilities for Zevra Therapeutics (ZVRA) over the last 10 years, with Dec 2024 value amounting to $138.5 million.

  • Zevra Therapeutics' Total Liabilities rose 12.46% to $137.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.0 million, marking a year-over-year increase of 12.46%. This contributed to the annual value of $138.5 million for FY2024, which is 25.35% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Total Liabilities of $138.5 million as of FY2024, which was up 25.35% from $110.5 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Total Liabilities peaked at $138.5 million during FY2024, and registered a low of $5.8 million during FY2021.
  • Moreover, its 3-year median value for Total Liabilities was $110.5 million (2023), whereas its average is $96.4 million.
  • In the last 5 years, Zevra Therapeutics' Total Liabilities plummeted by 92.50% in 2021 and then soared by 590.71% in 2022.
  • Zevra Therapeutics' Total Liabilities (Yearly) stood at $77.6 million in 2020, then crashed by 92.50% to $5.8 million in 2021, then soared by 590.71% to $40.2 million in 2022, then spiked by 174.65% to $110.5 million in 2023, then rose by 25.35% to $138.5 million in 2024.